Cargando…
Deviating HER2 test results in gastric cancer: analysis from the prospective multicenter VARIANZ study
PURPOSE: The prospective multicenter VARIANZ study aimed to identify resistance biomarkers for HER2-targeted treatment in advanced gastric and esophago-gastric junction cancer (GC, EGJC). HER2 test deviations were found in 90 (22.3%) of 404 cases (central versus local testing) and were associated wi...
Autores principales: | Kolbe, Katharina, Haffner, Ivonne, Schierle, Katrin, Maier, Dieter, Geier, Birgitta, Luber, Birgit, Bläker, Hendrik, Wittekind, Christian, Lordick, Florian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984518/ https://www.ncbi.nlm.nih.gov/pubmed/36030286 http://dx.doi.org/10.1007/s00432-022-04208-6 |
Ejemplares similares
-
HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study
por: Haffner, Ivonne, et al.
Publicado: (2021) -
Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines
por: Keller, Simone, et al.
Publicado: (2018) -
Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapies—the role of HAS2, SHB and HBEGF
por: Ebert, Karolin, et al.
Publicado: (2022) -
Data Resource: Vascular Risk in Adult New Zealanders (VARIANZ) datasets
por: Mehta, S, et al.
Publicado: (2019) -
Metabolomic therapy response prediction in pretherapeutic tissue biopsies for trastuzumab in patients with HER2‐positive advanced gastric cancer
por: Kunzke, Thomas, et al.
Publicado: (2021)